Zai Lab (NASDAQ:ZLAB – Get Free Report) and Evogene (NASDAQ:EVGN – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.
Profitability
This table compares Zai Lab and Evogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zai Lab | -44.91% | -31.15% | -18.17% |
| Evogene | -694.18% | -156.53% | -86.80% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Zai Lab and Evogene, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zai Lab | 1 | 1 | 4 | 1 | 2.71 |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
Zai Lab currently has a consensus price target of $37.25, indicating a potential upside of 40.99%. Given Zai Lab’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Zai Lab is more favorable than Evogene.
Earnings & Valuation
This table compares Zai Lab and Evogene”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zai Lab | $460.16 million | 7.18 | -$175.54 million | ($1.79) | -14.76 |
| Evogene | $3.85 million | 0.90 | -$8.48 million | ($0.91) | -0.43 |
Evogene has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Zai Lab has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Evogene has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.
Institutional and Insider Ownership
41.6% of Zai Lab shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Zai Lab beats Evogene on 10 of the 15 factors compared between the two stocks.
About Zai Lab
Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.
About Evogene
Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms. Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.
